PAH, phenylalanine hydroxylase, 5053

N. diseases: 219; N. variants: 394
Disease: Chronic thromboembolic pulmonary hypertension ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2363973
Disease: Chronic thromboembolic pulmonary hypertension
Chronic thromboembolic pulmonary hypertension 		0.080 Biomarker disease BEFREE This first randomised trial in PAH/CTEPH patients with exercise-induced hypoxaemia demonstrates that DOXT improves exercise capacity, quality of life and functional class. 31073087 2019
CUI: C2363973
Disease: Chronic thromboembolic pulmonary hypertension
Chronic thromboembolic pulmonary hypertension 		0.080 Biomarker disease BEFREE <b>Expert opinion</b>: Drugs approved for PAH have recently shown excellent efficacy in patients with non-operable CTEPH. 31545126 2019
CUI: C2363973
Disease: Chronic thromboembolic pulmonary hypertension
Chronic thromboembolic pulmonary hypertension 		0.080 Biomarker disease BEFREE This is the first systematic review and meta-analysis of randomized controlled trials revealing a positive role of PAH-targeted therapies in CTEPH. 31059198 2019
CUI: C2363973
Disease: Chronic thromboembolic pulmonary hypertension
Chronic thromboembolic pulmonary hypertension 		0.080 Biomarker disease BEFREE In this review, we summarize the achievements and unresolved problems of PAH-targeted therapy for CTEPH over the last decade. 31044326 2019
CUI: C2363973
Disease: Chronic thromboembolic pulmonary hypertension
Chronic thromboembolic pulmonary hypertension 		0.080 Biomarker disease BEFREE Whether daily activity assessments provide additional information to simple walk distance on risk factor profiles during follow-up in patients with PAH/CTEPH remains to be clarified. 31263960 2019
CUI: C2363973
Disease: Chronic thromboembolic pulmonary hypertension
Chronic thromboembolic pulmonary hypertension 		0.080 Biomarker disease BEFREE Correction to: Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH. 29616325 2018
CUI: C2363973
Disease: Chronic thromboembolic pulmonary hypertension
Chronic thromboembolic pulmonary hypertension 		0.080 Biomarker disease BEFREE In patients with PAH/CTEPH, very short-term exposure to moderate hypoxia similar to 2600 m altitude or during commercial air travel did not deteriorate hemodynamics. 29891241 2018
CUI: C2363973
Disease: Chronic thromboembolic pulmonary hypertension
Chronic thromboembolic pulmonary hypertension 		0.080 Biomarker disease BEFREE Patients with PAH/CTEPH may therefore benefit from oxygen therapy during daily physical activities and training. 28329240 2017